About Piramal Pharma Limited
Data last updated: 14 July 2026
Piramal Pharma Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 04 March 2020, the company has been in operation for over 6 years.
Registered with ROC Mumbai under CIN L24297MH2020PLC338592. Listed on BSE: 543635.
Capital: an authorised share capital of ₹3,000 Cr and a paid-up capital of ₹1,331.35 Cr. It is led by directors including Peter D Deyoung and Ramadorai Subramanian.
Last AGM: 30 July 2025. Financial statements filed for year ended 31 March 2025. Office: Ananta Building Piramal Corporate Park, Mumbai, Maharashtra.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹8,869.08 Cr, a decline of 3.08% compared to the previous year. The net worth stands at ₹8,162.62 Cr (up 0.46% YoY). Total assets are valued at ₹17,965 Cr (up 14.59% YoY).
The company has a workforce of approximately 3,851 employees as per the latest available data. Its group structure includes 1 subsidiary.
The company is associated with 4 brands - Piramal Pharma Solutions, Piramal Realty, Piramal Pharma, Piramal Group. As per MCA filings, the company has open charges of ₹2,430 Cr and satisfied charges of ₹1,000 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website piramal.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered AddressAnanta Building Piramal Corporate Park, Opp. Fire Brigade Kamani Junction Lbs Marg Kurla (West), Mumbai, Maharashtra, India – 400070
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Piramal Pharma Limited
Piramal Pharma Limited has one previous CIN (Corporate Identification Number): U24297MH2020PLC338592. The current CIN is L24297MH2020PLC338592, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24297MH2020PLC338592 | Current |
| U24297MH2020PLC338592 | Previous |
Associated Brands with Piramal Pharma Limited
Piramal Pharma Limited operates multiple associated brands including Piramal Pharma Solutions, Piramal Realty, and Piramal Pharma. These brands represent Piramal Pharma Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Serves as a contract manufacturer of pharmaceutical products for industry partners. | piramalpharmasolutions.com | |
| Development services for residential, commercial, and mixed-use projects are provided. | piramalrealty.com | |
| Innovative healthcare solutions are delivered through end-to-end manufacturing capabilities. | piramalpharma.com | |
| Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate | piramal.com |
Competitors & Alternatives of Piramal Pharma Limited
Brands and companies operating in the same space as Piramal Pharma Limited include Merck, Roivant Sciences, Amgen and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Merck
|
Pharmaceutical products are manufactured and marketed worldwide. | Kenilworth, United Kingdom, United Kingdom | 1891 |
Roivant Sciences
|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | New York, United States, United States | 2014 |
Amgen
|
Developer of pharmaceutical products for treating multiple diseases | Thousand Oaks, United States, United States | 1980 |
AbbVie
|
Biopharmaceutical research and drug development are conducted globally by AbbVie. | Chicago, United States, United States | 2012 |
Lilly
|
Traditional pharmaceutical medicines are developed for multiple health fields. | United States | 1876 |
Godrej Properties
|
Residential and commercial properties are developed by Godrej Properties. | Mumbai, India, India | 1990 |
Bausch & Lomb
|
Ophthalmic pharmaceuticals and instruments are developed for eye care. | Bridgewater, United States, United States | 1853 |
Roche
|
Pharmaceuticals and diagnostics kits are developed for various diseases. | Basel, Switzerland, Switzerland | 1896 |
Abzena
|
Provider of antibody discovery, cell line development, and bio analytics services | Cambridge, United Kingdom, United Kingdom | 2001 |
Vingroup
|
Real estate development and management services are offered by Vingroup. | Hanoi, Vietnam, Vietnam | 1993 |
Business Activity of Piramal Pharma Limited
Piramal Pharma Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Piramal Pharma Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Piramal Pharma Limited
Piramal Pharma Limited is audited by Suresh Surana & Associates LLP (ICAI peer reviewed, certificate valid till 2028-03-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Suresh Surana & Associates LLP (ICAI peer reviewed, certificate valid till 2028-03-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Piramal Pharma Limited
Piramal Pharma Limited is currently managed by 10 directors, with 2 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Peter D Deyoung
Also directs:
Piramal Pharma Limited
|
Whole-Time Director | 04 Mar 2020 | 6 Years 5 Months | Current |
|
Ramadorai Subramanian
Also directs:
Piramal Pharma Limited, Dsp Asset Managers Private Limited, British Asian India Foundation and 4 more
|
Director | 09 Feb 2021 | 5 Years 6 Months | Current |
|
Jairaj Manohar Purandare
Also directs:
Piramal Pharma Limited, J M Purandare & Co Llp, Cie Automotive India Limited and 4 more
|
Director | 09 Feb 2021 | 5 Years 6 Months | Current |
|
Sridhar Gorthi
Also directs:
Piramal Pharma Limited, Snark Capital Advisors Llp, Kshna Capital Advisors Llp and 4 more
|
Director | 30 Mar 2022 | 4 Years 4 Months | Current |
|
Nandini Ajay Piramal
Also directs:
Piramal Pharma Limited, Montane Ventures Private Limited, Piramal Water Private Limited and 1 more
|
Whole-Time Director | 04 Mar 2020 | 6 Years 5 Months | Current |
|
Vivek Valsaraj
Also directs:
Piramal Pharma Limited, Abbvie Therapeutics India Private Limited
|
Whole-Time Director | 09 Feb 2022 | 4 Years 6 Months | Current |
Financials of Piramal Pharma Limited FY 2026 filings available
Piramal Pharma Limited reported revenue of ₹8,869.08 Cr (down 3.08% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Revenue from Operations | ₹8,869.08 Cr | ₹9,151.18 Cr | ₹8,171.16 Cr | ₹7,081.55 Cr |
| Other Income | ₹213.3 Cr | ₹134.81 Cr | ₹175.39 Cr | ₹225.11 Cr |
| Total Income | ₹9,082.38 Cr | ₹9,285.99 Cr | ₹8,346.55 Cr | ₹7,306.66 Cr |
| Cost of Materials Consumed | ₹1,995.85 Cr | ₹2,055.74 Cr | ₹1,976.83 Cr | ₹1,682.46 Cr |
| Purchases of Stock-in-Trade | ₹1,430.53 Cr | ₹1,417.32 Cr | ₹1,175.77 Cr | ₹952.2 Cr |
| Changes in Inventories | -₹187.84 Cr | -₹241.41 Cr | -₹198.6 Cr | ₹68.64 Cr |
| Employee Benefit Expense | ₹2,415.92 Cr | ₹2,307.47 Cr | ₹2,029.5 Cr | ₹1,896.35 Cr |
| Finance Costs | ₹340.8 Cr | ₹421.59 Cr | ₹448.49 Cr | ₹344.18 Cr |
| Depreciation & Amortisation | ₹831.24 Cr | ₹816.34 Cr | ₹740.57 Cr | ₹676.69 Cr |
| Other Expenses | ₹2,293 Cr | ₹2,167.23 Cr | ₹1,991.4 Cr | ₹1,853.66 Cr |
| Total Expenses | ₹9,119.5 Cr | ₹8,944.28 Cr | ₹8,163.96 Cr | ₹7,474.18 Cr |
| Profit Before Exceptional Items & Tax | -₹37.12 Cr | ₹341.71 Cr | ₹182.59 Cr | -₹167.52 Cr |
| Exceptional Items | -₹196.14 Cr | ₹0 | -₹62.79 Cr | -₹6.96 Cr |
| Profit Before Tax | -₹233.26 Cr | ₹341.71 Cr | ₹119.8 Cr | -₹174.48 Cr |
| Total Tax Expense | ₹149.88 Cr | ₹323.51 Cr | ₹161.47 Cr | ₹66.31 Cr |
| Net Profit | -₹325.94 Cr | ₹91.13 Cr | ₹17.82 Cr | -₹186.46 Cr |
| attributable to Owners | -₹325.94 Cr | ₹91.13 Cr | - | - |
| attributable to NCI | ₹0 | ₹0 | ₹0 | - |
| Other Comprehensive Income | ₹338.38 Cr | ₹79.83 Cr | ₹56.72 Cr | ₹175.8 Cr |
| Total Comprehensive Income | ₹12.44 Cr | ₹170.96 Cr | ₹74.54 Cr | -₹10.66 Cr |
| EBITDA (computed) | ₹1,134.92 Cr | ₹1,579.64 Cr | ₹1,371.65 Cr | ₹853.35 Cr |
| Basic EPS | ₹-2.46 | ₹0.69 | ₹0.14 | ₹-1.57 |
| Diluted EPS | ₹-2.46 | ₹0.68 | ₹0.14 | ₹-1.57 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹17,965 Cr | ₹15,678 Cr | ₹15,312 Cr | ₹14,523 Cr |
| Non-current Assets | ₹10,773 Cr | ₹9,880.6 Cr | ₹9,847.34 Cr | ₹9,687.08 Cr |
| Current Assets | ₹7,191.66 Cr | ₹5,796.99 Cr | ₹5,464.47 Cr | ₹4,835.48 Cr |
| Property, Plant & Equipment | ₹4,450.71 Cr | ₹4,175.98 Cr | ₹3,872.64 Cr | ₹3,363.04 Cr |
| Inventories | ₹3,064.44 Cr | ₹2,312.7 Cr | ₹2,175.88 Cr | ₹1,681.37 Cr |
| Trade Receivables | ₹2,157.67 Cr | ₹2,349.52 Cr | ₹2,134.43 Cr | ₹1,799.34 Cr |
| Cash & Equivalents | ₹1,199.88 Cr | ₹368.98 Cr | ₹356.82 Cr | ₹195.59 Cr |
| Equity (Net Worth) | ₹8,162.62 Cr | ₹8,125.47 Cr | ₹7,911.37 Cr | ₹6,773.5 Cr |
| Equity Share Capital | ₹1,327.16 Cr | ₹1,324.35 Cr | ₹1,322.95 Cr | ₹1,193.32 Cr |
| Borrowings (Non-current) | ₹4,299.97 Cr | ₹3,214.07 Cr | ₹2,483.75 Cr | ₹3,383.54 Cr |
| Borrowings (Current) | ₹1,195.51 Cr | ₹1,506.2 Cr | ₹2,075.11 Cr | ₹2,121.23 Cr |
| Total Debt (computed) | ₹5,495.48 Cr | ₹4,720.27 Cr | ₹4,558.86 Cr | ₹5,504.77 Cr |
| Current Liabilities | ₹4,758.28 Cr | ₹3,766.27 Cr | ₹4,369.3 Cr | ₹3,843.05 Cr |
| Total Liabilities | ₹9,802.42 Cr | ₹7,552.12 Cr | ₹7,400.44 Cr | ₹7,749.06 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Cash Flow | ₹1,652.59 Cr | ₹892.3 Cr | ₹1,004.54 Cr | ₹483.89 Cr |
| Investing Cash Flow | -₹826.03 Cr | -₹477.46 Cr | -₹434.01 Cr | -₹1,338.78 Cr |
| Financing Cash Flow | -₹38.97 Cr | -₹440.83 Cr | -₹422.36 Cr | ₹817.79 Cr |
| Capital Expenditure | ₹890.02 Cr | ₹664.38 Cr | ₹712.04 Cr | ₹964.75 Cr |
| Free Cash Flow (computed) | ₹762.57 Cr | ₹227.92 Cr | ₹292.5 Cr | -₹480.86 Cr |
| Dividends Paid | ₹18.55 Cr | ₹14.47 Cr | ₹0 | ₹67 Cr |
| Net Change in Cash | ₹793.94 Cr | -₹36.87 Cr | ₹165.96 Cr | -₹31.95 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹2,751.77 Cr | ₹2,139.87 Cr | ₹2,043.72 Cr | ₹1,933.71 Cr | ₹2,754.07 Cr | ₹2,204.22 Cr | ₹2,241.75 Cr | ₹1,951.14 Cr | ₹2,552.36 Cr | ₹1,958.57 Cr | ₹1,911.38 Cr | ₹1,748.85 Cr |
| Other Income | ₹46.06 Cr | ₹43.24 Cr | ₹65.6 Cr | ₹58.4 Cr | ₹42.03 Cr | ₹12.13 Cr | ₹61.11 Cr | ₹19.54 Cr | ₹26.38 Cr | ₹61.51 Cr | ₹49.19 Cr | ₹38.31 Cr |
| Total Income | ₹2,797.83 Cr | ₹2,183.11 Cr | ₹2,109.32 Cr | ₹1,992.11 Cr | ₹2,796.1 Cr | ₹2,216.35 Cr | ₹2,302.86 Cr | ₹1,970.68 Cr | ₹2,578.74 Cr | ₹2,020.08 Cr | ₹1,960.57 Cr | ₹1,787.16 Cr |
| Cost of Materials Consumed | ₹482.59 Cr | ₹505.48 Cr | ₹483.42 Cr | ₹524.35 Cr | ₹203.68 Cr | ₹805.44 Cr | ₹575.14 Cr | ₹471.48 Cr | ₹400.08 Cr | ₹627.63 Cr | ₹531.72 Cr | ₹417.4 Cr |
| Purchases of Stock-in-Trade | ₹336.03 Cr | ₹376.84 Cr | ₹374.83 Cr | ₹342.83 Cr | ₹546.72 Cr | ₹161.06 Cr | ₹394.77 Cr | ₹314.77 Cr | ₹436.06 Cr | ₹227.93 Cr | ₹243.59 Cr | ₹268.19 Cr |
| Changes in Inventories | ₹237.05 Cr | -₹96.01 Cr | -₹155.75 Cr | -₹173.13 Cr | ₹204.58 Cr | -₹160.67 Cr | -₹173.44 Cr | -₹111.88 Cr | ₹178.25 Cr | -₹180.41 Cr | -₹137.58 Cr | -₹58.86 Cr |
| Employee Benefit Expense | ₹586.02 Cr | ₹599.85 Cr | ₹611.46 Cr | ₹618.59 Cr | ₹612.01 Cr | ₹556.24 Cr | ₹559.53 Cr | ₹579.69 Cr | ₹494.15 Cr | ₹523.78 Cr | ₹516.03 Cr | ₹495.54 Cr |
| Finance Costs | ₹82.99 Cr | ₹89.24 Cr | ₹82.42 Cr | ₹86.15 Cr | ₹103.68 Cr | ₹103.31 Cr | ₹107.64 Cr | ₹106.96 Cr | ₹114.22 Cr | ₹105.88 Cr | ₹109.87 Cr | ₹118.52 Cr |
| Depreciation & Amortisation | ₹218.38 Cr | ₹212.74 Cr | ₹202.84 Cr | ₹197.28 Cr | ₹242.76 Cr | ₹196.81 Cr | ₹192.22 Cr | ₹184.55 Cr | ₹196.13 Cr | ₹186.32 Cr | ₹184.51 Cr | ₹173.61 Cr |
| Other Expenses | ₹649.57 Cr | ₹557.98 Cr | ₹571.07 Cr | ₹514.37 Cr | ₹626.09 Cr | ₹504.41 Cr | ₹544.14 Cr | ₹492.59 Cr | ₹513.89 Cr | ₹491.27 Cr | ₹491.98 Cr | ₹494.27 Cr |
| Total Expenses | ₹2,592.63 Cr | ₹2,246.12 Cr | ₹2,170.29 Cr | ₹2,110.44 Cr | ₹2,539.52 Cr | ₹2,166.6 Cr | ₹2,200 Cr | ₹2,038.16 Cr | ₹2,332.78 Cr | ₹1,982.4 Cr | ₹1,940.12 Cr | ₹1,908.66 Cr |
| Profit Before Exceptional Items & Tax | ₹205.2 Cr | -₹63.01 Cr | -₹60.97 Cr | -₹118.33 Cr | ₹256.58 Cr | ₹49.75 Cr | ₹102.86 Cr | -₹67.48 Cr | ₹245.96 Cr | ₹37.68 Cr | ₹20.45 Cr | -₹121.5 Cr |
| Exceptional Items | -₹175.77 Cr | -₹41.11 Cr | ₹0 | ₹20.74 Cr | ₹0 | ₹0 | ₹0 | ₹0 | -₹30.52 Cr | -₹32.27 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹29.43 Cr | -₹104.12 Cr | -₹60.97 Cr | -₹97.59 Cr | ₹256.58 Cr | ₹49.75 Cr | ₹102.86 Cr | -₹67.48 Cr | ₹215.44 Cr | ₹5.41 Cr | ₹20.45 Cr | -₹121.5 Cr |
| Total Tax Expense | ₹51.83 Cr | ₹42.33 Cr | ₹53.04 Cr | ₹2.68 Cr | ₹119.3 Cr | ₹63.12 Cr | ₹97.53 Cr | ₹43.56 Cr | ₹126.21 Cr | ₹9.25 Cr | ₹34.54 Cr | -₹8.52 Cr |
| Net Profit | -₹8.82 Cr | -₹136.19 Cr | -₹99.22 Cr | -₹81.7 Cr | ₹153.5 Cr | ₹3.68 Cr | ₹22.59 Cr | -₹88.64 Cr | ₹101.27 Cr | ₹10.11 Cr | ₹5.02 Cr | -₹98.58 Cr |
| attributable to Owners | -₹8.82 Cr | -₹136.19 Cr | -₹99.22 Cr | -₹81.7 Cr | ₹153.5 Cr | ₹3.68 Cr | ₹22.59 Cr | -₹88.64 Cr | - | - | - | - |
| attributable to NCI | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | - |
| Other Comprehensive Income | ₹163.28 Cr | ₹60.05 Cr | ₹70.91 Cr | ₹44.14 Cr | ₹13.95 Cr | ₹15.07 Cr | ₹54.96 Cr | -₹4.15 Cr | -₹22.22 Cr | ₹43.83 Cr | ₹8.5 Cr | ₹26.61 Cr |
| Total Comprehensive Income | ₹154.46 Cr | -₹76.14 Cr | -₹28.31 Cr | -₹37.56 Cr | ₹167.45 Cr | ₹18.75 Cr | ₹77.55 Cr | -₹92.79 Cr | ₹79.05 Cr | ₹53.94 Cr | ₹13.52 Cr | -₹71.97 Cr |
| EBITDA (computed) | ₹506.57 Cr | ₹238.97 Cr | ₹224.29 Cr | ₹165.1 Cr | ₹603.02 Cr | ₹349.87 Cr | ₹402.72 Cr | ₹224.03 Cr | ₹556.31 Cr | ₹329.88 Cr | ₹314.83 Cr | ₹170.63 Cr |
| Basic EPS | ₹-0.07 | ₹-1.03 | ₹-0.75 | ₹-0.62 | ₹1.16 | ₹0.03 | ₹0.17 | ₹-0.67 | ₹0.77 | ₹0.08 | ₹0.04 | ₹-0.83 |
| Diluted EPS | ₹-0.07 | ₹-1.03 | ₹-0.75 | ₹-0.62 | ₹1.16 | ₹0.03 | ₹0.17 | ₹-0.67 | ₹0.77 | ₹0.08 | ₹0.04 | ₹-0.83 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Revenue from Operations | ₹4,782.01 Cr | ₹5,285.71 Cr | ₹4,390.11 Cr | ₹3,443.22 Cr |
| Other Income | ₹662.73 Cr | ₹207.35 Cr | ₹202.06 Cr | ₹341.07 Cr |
| Total Income | ₹5,444.74 Cr | ₹5,493.06 Cr | ₹4,592.17 Cr | ₹3,784.29 Cr |
| Cost of Materials Consumed | ₹1,342.7 Cr | ₹1,596.93 Cr | ₹1,545.55 Cr | ₹1,166.48 Cr |
| Purchases of Stock-in-Trade | ₹866.18 Cr | ₹733.6 Cr | ₹624.91 Cr | ₹548.69 Cr |
| Changes in Inventories | -₹138.98 Cr | -₹84.57 Cr | -₹61.62 Cr | ₹53.31 Cr |
| Employee Benefit Expense | ₹744.82 Cr | ₹736.19 Cr | ₹613.93 Cr | ₹548.5 Cr |
| Finance Costs | ₹79.95 Cr | ₹114.56 Cr | ₹107.1 Cr | ₹115.87 Cr |
| Depreciation & Amortisation | ₹255.5 Cr | ₹222.09 Cr | ₹205.26 Cr | ₹192.08 Cr |
| Other Expenses | ₹1,325.29 Cr | ₹1,263.12 Cr | ₹1,049.42 Cr | ₹1,028.71 Cr |
| Total Expenses | ₹4,475.46 Cr | ₹4,581.92 Cr | ₹4,084.55 Cr | ₹3,653.64 Cr |
| Profit Before Exceptional Items & Tax | ₹969.28 Cr | ₹911.14 Cr | ₹507.62 Cr | ₹130.65 Cr |
| Exceptional Items | -₹92.51 Cr | ₹0 | ₹0 | -₹6.96 Cr |
| Profit Before Tax | ₹876.77 Cr | ₹911.14 Cr | ₹507.62 Cr | ₹123.69 Cr |
| Total Tax Expense | ₹176.76 Cr | ₹219.74 Cr | ₹116.4 Cr | ₹54.19 Cr |
| Net Profit | ₹700.01 Cr | ₹691.4 Cr | ₹391.22 Cr | ₹69.5 Cr |
| Other Comprehensive Income | -₹35.73 Cr | ₹5.5 Cr | -₹4.26 Cr | -₹18.35 Cr |
| Total Comprehensive Income | ₹664.28 Cr | ₹696.9 Cr | ₹386.96 Cr | ₹51.15 Cr |
| EBITDA (computed) | ₹1,304.73 Cr | ₹1,247.79 Cr | ₹819.98 Cr | ₹438.6 Cr |
| Basic EPS | ₹5.28 | ₹5.22 | ₹3.05 | ₹0.58 |
| Diluted EPS | ₹5.25 | ₹5.20 | ₹3.05 | ₹0.58 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹11,753 Cr | ₹10,392 Cr | ₹9,550.88 Cr | ₹8,042.4 Cr |
| Non-current Assets | ₹7,355.17 Cr | ₹6,855.95 Cr | ₹6,259.33 Cr | ₹5,693.72 Cr |
| Current Assets | ₹4,398.1 Cr | ₹3,535.88 Cr | ₹3,291.55 Cr | ₹2,348.68 Cr |
| Property, Plant & Equipment | ₹2,021.5 Cr | ₹2,010.75 Cr | ₹1,727.28 Cr | ₹1,673.56 Cr |
| Inventories | ₹1,873.39 Cr | ₹1,205.35 Cr | ₹1,153.04 Cr | ₹818.61 Cr |
| Trade Receivables | ₹1,405.84 Cr | ₹1,666.69 Cr | ₹1,331.38 Cr | ₹909.56 Cr |
| Cash & Equivalents | ₹559.03 Cr | ₹163.87 Cr | ₹228.8 Cr | ₹54.28 Cr |
| Equity (Net Worth) | ₹8,141.13 Cr | ₹7,452.54 Cr | ₹6,712.07 Cr | ₹5,261.79 Cr |
| Equity Share Capital | ₹1,327.16 Cr | ₹1,324.35 Cr | ₹1,322.95 Cr | ₹1,193.32 Cr |
| Borrowings (Non-current) | ₹420.86 Cr | ₹356.84 Cr | ₹363.94 Cr | ₹592.34 Cr |
| Borrowings (Current) | ₹289.03 Cr | ₹865.09 Cr | ₹787.95 Cr | ₹1,034.94 Cr |
| Total Debt (computed) | ₹709.89 Cr | ₹1,221.93 Cr | ₹1,151.89 Cr | ₹1,627.28 Cr |
| Current Liabilities | ₹2,766.28 Cr | ₹2,306.49 Cr | ₹2,227.82 Cr | ₹1,951.29 Cr |
| Total Liabilities | ₹3,612.14 Cr | ₹2,939.29 Cr | ₹2,838.81 Cr | ₹2,780.61 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Cash Flow | ₹1,328.12 Cr | ₹548.77 Cr | ₹358.29 Cr | ₹71.52 Cr |
| Investing Cash Flow | -₹317.83 Cr | -₹549.98 Cr | -₹635.52 Cr | -₹435.05 Cr |
| Financing Cash Flow | -₹615.13 Cr | -₹61.74 Cr | ₹451.38 Cr | ₹290.12 Cr |
| Capital Expenditure | ₹297.55 Cr | ₹282.78 Cr | ₹325.56 Cr | ₹244.86 Cr |
| Free Cash Flow (computed) | ₹1,030.57 Cr | ₹265.99 Cr | ₹32.73 Cr | -₹173.34 Cr |
| Dividends Paid | ₹18.54 Cr | ₹14.47 Cr | ₹0 | ₹67 Cr |
| Net Change in Cash | ₹395.16 Cr | -₹64.93 Cr | ₹174.52 Cr | -₹73.41 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,489.06 Cr | ₹1,195.81 Cr | ₹1,127.26 Cr | ₹969.88 Cr | ₹1,689.8 Cr | ₹1,248.32 Cr | ₹1,284.39 Cr | ₹1,063.2 Cr | ₹1,525.3 Cr | ₹1,024.14 Cr | ₹994.24 Cr | ₹846.43 Cr |
| Other Income | ₹183.69 Cr | ₹96.15 Cr | ₹201.97 Cr | ₹180.92 Cr | ₹39.51 Cr | ₹24.7 Cr | ₹106.38 Cr | ₹36.76 Cr | ₹53.19 Cr | ₹33.11 Cr | ₹89.08 Cr | ₹26.68 Cr |
| Total Income | ₹1,672.75 Cr | ₹1,291.96 Cr | ₹1,329.23 Cr | ₹1,150.8 Cr | ₹1,729.31 Cr | ₹1,273.02 Cr | ₹1,390.77 Cr | ₹1,099.96 Cr | ₹1,578.49 Cr | ₹1,057.25 Cr | ₹1,083.32 Cr | ₹873.11 Cr |
| Cost of Materials Consumed | ₹234.93 Cr | ₹347.06 Cr | ₹350.95 Cr | ₹409.76 Cr | ₹336.72 Cr | ₹474.23 Cr | ₹380.22 Cr | ₹405.76 Cr | ₹417.52 Cr | ₹444.94 Cr | ₹356.76 Cr | ₹326.33 Cr |
| Purchases of Stock-in-Trade | ₹194.03 Cr | ₹264.03 Cr | ₹215.85 Cr | ₹192.27 Cr | ₹149.93 Cr | ₹174.42 Cr | ₹232.81 Cr | ₹176.44 Cr | ₹145.86 Cr | ₹171.21 Cr | ₹156.09 Cr | ₹151.75 Cr |
| Changes in Inventories | ₹225.25 Cr | -₹78.19 Cr | -₹110.17 Cr | -₹175.87 Cr | ₹236.32 Cr | -₹117.13 Cr | -₹71.41 Cr | -₹132.35 Cr | ₹135.74 Cr | -₹120.72 Cr | -₹11.59 Cr | -₹65.05 Cr |
| Employee Benefit Expense | ₹166.55 Cr | ₹187.8 Cr | ₹188.52 Cr | ₹201.95 Cr | ₹198.96 Cr | ₹173.55 Cr | ₹176.72 Cr | ₹186.96 Cr | ₹152.88 Cr | ₹150.56 Cr | ₹151.44 Cr | ₹159.05 Cr |
| Finance Costs | ₹19.5 Cr | ₹16.84 Cr | ₹20.38 Cr | ₹23.23 Cr | ₹30.56 Cr | ₹29.17 Cr | ₹29.95 Cr | ₹24.88 Cr | ₹27.66 Cr | ₹17.42 Cr | ₹28.22 Cr | ₹33.8 Cr |
| Depreciation & Amortisation | ₹70.12 Cr | ₹64.69 Cr | ₹61.25 Cr | ₹59.44 Cr | ₹61.17 Cr | ₹55.46 Cr | ₹53.61 Cr | ₹51.85 Cr | ₹52.5 Cr | ₹51.56 Cr | ₹50.83 Cr | ₹50.37 Cr |
| Other Expenses | ₹364.95 Cr | ₹307.86 Cr | ₹355.04 Cr | ₹297.44 Cr | ₹351.29 Cr | ₹323.91 Cr | ₹313.16 Cr | ₹274.76 Cr | ₹283.66 Cr | ₹252.62 Cr | ₹255.38 Cr | ₹257.76 Cr |
| Total Expenses | ₹1,275.33 Cr | ₹1,110.09 Cr | ₹1,081.82 Cr | ₹1,008.22 Cr | ₹1,364.95 Cr | ₹1,113.61 Cr | ₹1,115.06 Cr | ₹988.3 Cr | ₹1,215.82 Cr | ₹967.59 Cr | ₹987.13 Cr | ₹914.01 Cr |
| Profit Before Exceptional Items & Tax | ₹397.42 Cr | ₹181.87 Cr | ₹247.41 Cr | ₹142.58 Cr | ₹364.36 Cr | ₹159.41 Cr | ₹275.71 Cr | ₹111.66 Cr | ₹362.67 Cr | ₹89.66 Cr | ₹96.19 Cr | -₹40.9 Cr |
| Exceptional Items | -₹65.57 Cr | -₹26.94 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹331.85 Cr | ₹154.93 Cr | ₹247.41 Cr | ₹142.58 Cr | ₹364.36 Cr | ₹159.41 Cr | ₹275.71 Cr | ₹111.66 Cr | ₹362.67 Cr | ₹89.66 Cr | ₹96.19 Cr | -₹40.9 Cr |
| Total Tax Expense | ₹70.22 Cr | ₹26.02 Cr | ₹51.08 Cr | ₹29.44 Cr | ₹87.09 Cr | ₹40.61 Cr | ₹65.65 Cr | ₹26.39 Cr | ₹89.59 Cr | ₹15.32 Cr | ₹19.03 Cr | -₹7.54 Cr |
| Net Profit | ₹261.63 Cr | ₹128.91 Cr | ₹196.33 Cr | ₹113.14 Cr | ₹277.27 Cr | ₹118.8 Cr | ₹210.06 Cr | ₹85.27 Cr | ₹273.08 Cr | ₹74.34 Cr | ₹77.16 Cr | -₹33.36 Cr |
| Other Comprehensive Income | -₹10.14 Cr | ₹4.54 Cr | -₹27.43 Cr | -₹2.71 Cr | ₹13.43 Cr | -₹3.53 Cr | -₹1.1 Cr | -₹3.3 Cr | -₹2.08 Cr | ₹2.02 Cr | -₹4.96 Cr | ₹75.5 Lakh |
| Total Comprehensive Income | ₹251.49 Cr | ₹133.45 Cr | ₹168.9 Cr | ₹110.43 Cr | ₹290.7 Cr | ₹115.27 Cr | ₹208.96 Cr | ₹81.97 Cr | ₹271 Cr | ₹76.36 Cr | ₹72.2 Cr | -₹32.6 Cr |
| EBITDA (computed) | ₹487.04 Cr | ₹263.4 Cr | ₹329.04 Cr | ₹225.25 Cr | ₹456.09 Cr | ₹244.04 Cr | ₹359.27 Cr | ₹188.39 Cr | ₹442.83 Cr | ₹158.64 Cr | ₹175.24 Cr | ₹43.28 Cr |
| Basic EPS | ₹1.97 | ₹0.97 | ₹1.48 | ₹0.85 | ₹2.09 | ₹0.90 | ₹1.59 | ₹0.64 | ₹2.06 | ₹0.56 | ₹0.61 | ₹-0.28 |
| Diluted EPS | ₹1.96 | ₹0.97 | ₹1.47 | ₹0.85 | ₹2.09 | ₹0.90 | ₹1.59 | ₹0.64 | ₹2.06 | ₹0.56 | ₹0.61 | ₹-0.28 |
Shareholding Pattern of Piramal Pharma Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 34.86%, foreign institutional investors hold 30.18%, domestic institutional investors hold 15.61%, retail and other public shareholders hold 19.01% of Piramal Pharma Limited. The company had 450,661 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 34.86% | 34.86% | 34.86% | 34.86% | 34.95% | 34.95% |
| Public | 64.81% | 64.70% | 64.63% | 64.57% | 64.71% | 64.65% |
| Employee Trusts | 0.34% | 0.44% | 0.51% | 0.57% | 0.34% | 0.40% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Promoters | 34.86% | 34.95% | 35.02% | 34.79% |
| Public | 64.81% | 64.71% | 64.61% | 64.82% |
| Employee Trusts | 0.34% | 0.34% | 0.37% | 0.39% |
| Promoter change (YoY, %pts) | -0.09 | -0.07 | +0.23 | - |
Board & Governance of Piramal Pharma Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Piramal Pharma Limited has 11 directors - 6 independent and 3 executive. The board is chaired by Nandini Piramal.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Nandini Piramal | Executive Director · Chairperson | 2020-03-04 | 1 |
| Peter DeYoung | Executive Director | 2020-03-04 | 1 |
| Vivek Valsaraj | Executive Director | 2022-02-09 | 1 |
| Jairaj Purandare | Non-Executive - Independent Director | 2021-02-09 | 4 |
| Peter Stevenson | Non-Executive - Independent Director | 2022-03-30 | 1 |
| Sridhar Gorthi | Non-Executive - Independent Director | 2022-03-30 | 3 |
| Vibha Paul Rishi | Non-Executive - Independent Director | 2022-08-30 | 4 |
| Nathalie Leitch | Non-Executive - Non Independent Director | 2025-01-28 | 1 |
| Amit Jain | Non-Executive - Non Independent Director | 2025-05-14 | 1 |
| Amit Soni | Non-Executive - Independent Director | 2026-02-09 | 1 |
| S. Ramadorai | Non-Executive - Independent Director | 2021-02-09 | 0 |
| Committee | Members |
|---|---|
| Audit Committee | Jairaj Purandare (Chairperson), Amit Soni, Sridhar Gorthi, S. Ramadorai |
| Nomination and remuneration committee | Sridhar Gorthi (Chairperson), Jairaj Purandare, Nandini Piramal, Vibha Paul Rishi, S. Ramadorai (Chairperson) |
| Stakeholders Relationship Committee | Vibha Paul Rishi (Chairperson), Nandini Piramal, Vivek Valsaraj |
| Risk Management Committee | Nandini Piramal (Chairperson), Jairaj Purandare, Sridhar Gorthi, Vibha Paul Rishi, Amit Jain, Peter Stevenson |
| Corporate Social Responsibility Committee | Jairaj Purandare (Chairperson), Nandini Piramal, Vivek Valsaraj |
Group Structure of Piramal Pharma Limited
Piramal Pharma Limited has 1 subsidiary company and 2 associated companies. This group structure data is as of FY 2023. The corporate group structure reflects Piramal Pharma Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Piramal Pharma Ii Private Limited | U24230MH2022PTC384232 | - |
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Piramal Pharma Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 May 2025 | Idbi Trusteeship Services Limited | ₹300 Cr | Open |
| 12 Dec 2024 | Idbi Trusteeship Services Limited | ₹100 Cr | Open |
| 10 Dec 2024 | Idbi Trusteeship Services Limited | ₹200 Cr | Open |
| 10 Dec 2024 | Idbi Trusteeship Services Limited | ₹100 Cr | Open |
| 10 Sep 2024 | Idbi Trusteeship Services Limited | ₹150 Cr | Open |
Total charge records: 20 View all charges
Employees and EPFO Compliance at Piramal Pharma Limited
Piramal Pharma Limited has a workforce of 3,851 employees as of Apr 02, 2024.
Employee and EPFO history for Piramal Pharma Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Piramal Pharma Limited
GST registrations and filing compliance for Piramal Pharma Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Piramal Pharma Limited
Credit ratings, litigation, and regulatory alerts for Piramal Pharma Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Piramal Pharma Limited
MSME payment history for Piramal Pharma Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Piramal Pharma Limited
Corporate group structure for Piramal Pharma Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Piramal Pharma Limited
MCA filings and documents for Piramal Pharma Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Piramal Pharma Limited
Recent News on Piramal Pharma Limited
Frequently Asked Questions about Piramal Pharma Limited
Piramal Pharma Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 04 March 2020 (6+ years old) and is registered under CIN L24297MH2020PLC338592. Listed on BSE: 543635. The company has 3,851 employees.
Piramal Pharma Limited reported revenue of ₹8,869.08 Cr for FY 2026 (down 3.08% YoY) based on consolidated NSE filings.
The current directors of Piramal Pharma Limited are:
- Peter D Deyoung - Whole-Time Director
- Ramadorai Subramanian - Director
- Jairaj Manohar Purandare - Director
- Sridhar Gorthi - Director
- Nandini Ajay Piramal - Whole-Time Director
- Vivek Valsaraj - Whole-Time Director
- Peter Andrew Stevenson - Director
- Nathalie Ann Leitch - Director
- Vibha Paul Rishi - Director
- Amit Jain - Director
The primary industry of Piramal Pharma Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Piramal Pharma Limited is listed on BSE with code 543635.
Piramal Pharma Limited can be reached at the registered office: Ananta Building Piramal Corporate Park, Opp. Fire Brigade Kamani Junction Lbs Marg Kurla West, Mumbai, Maharashtra, India – 400070, or through the website piramal.com.